Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement

NCT ID: NCT02674386

Last Updated: 2020-07-30

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

154 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-08-23

Study Completion Date

2019-07-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A4091064 is a multicenter, long-term observational study of subjects from tanezumab interventional studies (regardless of treatment group) who undergo a total knee, hip or shoulder replacement during participation in the study. The study is designed with a total duration of subject follow-up of 24 weeks after the total joint replacement surgery. There will be two methods of data collection utilized in this study: interview by site staff via the telephone and interactive web-response system (or paper if the subject has no access to the internet).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A4091064 is a long-term observational follow up study of subjects from tanezumab interventional studies A4091056, A4091057 or A4091058.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoarthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1

long-term observational study of subjects from tanezumab parent study

Group Type OTHER

Investigational Medical Product (IMP) administered in parent study

Intervention Type DRUG

IMP as administered in parent study. IMP would have been either placebo, tanezumab, celecoxib, naproxen or diclofenac administered in parent study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Investigational Medical Product (IMP) administered in parent study

IMP as administered in parent study. IMP would have been either placebo, tanezumab, celecoxib, naproxen or diclofenac administered in parent study.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Personally signed and dated informed consent document.
* Randomized and treated with subcutaneous investigational product in a tanezumab study and has completed the study or been withdrawn from the study.
* Actual or planned total knee, hip or shoulder replacement surgery during the tanezumab study.
* Willing and able to comply with scheduled visits and other study procedures.

Exclusion Criteria

\- None.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Eli Lilly and Company

INDUSTRY

Sponsor Role collaborator

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Central Alabama Research

Birmingham, Alabama, United States

Site Status

Alabama Clinical Therapeutics, LLC

Birmingham, Alabama, United States

Site Status

Alabama Orthopaedic Surgeons

Birmingham, Alabama, United States

Site Status

Cahaba Research Inc.

Birmingham, Alabama, United States

Site Status

Noble Clinical Research

Tucson, Arizona, United States

Site Status

Baptist Health Center for Clinical Research

Little Rock, Arkansas, United States

Site Status

Advanced Research Center, Inc.

Anaheim, California, United States

Site Status

Hope Clinical Research

Canoga Park, California, United States

Site Status

Marvel Clinical Research, LLC

Huntington Beach, California, United States

Site Status

Advances in Medicine

Palm Desert, California, United States

Site Status

Clinical Trials Research

Sacramento, California, United States

Site Status

California Research Foundation

San Diego, California, United States

Site Status

CITrials

Santa Ana, California, United States

Site Status

Stamford Therapeutics Consortium

Stamford, Connecticut, United States

Site Status

JEM Research Institute

Atlantis, Florida, United States

Site Status

Orthopedic Research Institute

Boynton Beach, Florida, United States

Site Status

Orthopaedic Associates of West Florida

Clearwater, Florida, United States

Site Status

Clinical Neuroscience Solutions, Inc.

Jacksonville, Florida, United States

Site Status

Clintex Research Group

Miami, Florida, United States

Site Status

Renstar Medical Research

Ocala, Florida, United States

Site Status

American Family Medical

Ocala, Florida, United States

Site Status

Sunshine Research Center

Opa-locka, Florida, United States

Site Status

Gulfcoast Research Institute, LLC

Sarasota, Florida, United States

Site Status

Kennedy White Orthopaedic Center

Sarasota, Florida, United States

Site Status

Stedman Clinical Trials

Tampa, Florida, United States

Site Status

Masters of Clinical Research, Inc.

Augusta, Georgia, United States

Site Status

North Georgia Clinical Research

Woodstock, Georgia, United States

Site Status

North Georgia Internal Medicine

Woodstock, Georgia, United States

Site Status

Injury Care Research

Boise, Idaho, United States

Site Status

Chicago Clinical Research Institute, Inc.

Chicago, Illinois, United States

Site Status

Northwestern University

Chicago, Illinois, United States

Site Status

Professional Research Network of Kansas, LLC

Wichita, Kansas, United States

Site Status

Best Clinical Trials, LLC

New Orleans, Louisiana, United States

Site Status

George Stanley Walker, MD

New Orleans, Louisiana, United States

Site Status

Great Lakes Research Group, Incorporated

Bay City, Michigan, United States

Site Status

Orthopaedic Associates of Michigan, PC

Grand Rapids, Michigan, United States

Site Status

Physician Research Collaboration, LLC

Lincoln, Nebraska, United States

Site Status

Drug Trials America

Hartsdale, New York, United States

Site Status

Remington-Davis, Incorporated

Columbus, Ohio, United States

Site Status

Optimed Research LTD

Columbus, Ohio, United States

Site Status

AC Clinical Research

Tiffin, Ohio, United States

Site Status

Founders Research Corporation

Philadelphia, Pennsylvania, United States

Site Status

Abigail R. Neiman, MD, PA

Houston, Texas, United States

Site Status

Advances In Health

Houston, Texas, United States

Site Status

Mercury Clinical Research, Inc.

Houston, Texas, United States

Site Status

BI Research Center

Houston, Texas, United States

Site Status

ClinRx Research

Richardson, Texas, United States

Site Status

DCT - Stone Oak, LLC dba Discovery Clinical Trials

San Antonio, Texas, United States

Site Status

Mercury Clinical Research

Webster, Texas, United States

Site Status

Spectrum Medical, Inc.

Danville, Virginia, United States

Site Status

Northwest Clinical Research Center

Bellevue, Washington, United States

Site Status

CMAX Clinical Research Pty Ltd

Adelaide, South Australia, Australia

Site Status

Dawson Road Medical Centre

Guelph, Ontario, Canada

Site Status

Rebecca Medical Associates

Oakville, Ontario, Canada

Site Status

Recherche Clinique Sigma inc

Québec, Quebec, Canada

Site Status

Centre de recherche Saint-Louis

Québec, Quebec, Canada

Site Status

Rheumazentrum Prof. Dr. med Gunther Neeck

Bad Doberan, , Germany

Site Status

Tolna Megyei Balassa Janos Korhaz, Ortopediai Osztaly

Szekszárd, , Hungary

Site Status

Azienda Ospedaliero-Universitaria E Policlinico Umberto I

Rome, , Italy

Site Status

Omuro Orthopedic Clinic

Himeji, Hyōgo, Japan

Site Status

Nakajo Orthopedic Clinic

Sendai, Miyagi, Japan

Site Status

Marunouchi Hospital

Matsumoto, Nagano, Japan

Site Status

National Hospital Organization Osaka Minami Medical Center

Kawachi-Nagano, Osaka, Japan

Site Status

Osaka University Hospital

Suita, Osaka, Japan

Site Status

Saules seimos medicinos centras

Kaunas, , Lithuania

Site Status

South Pacific Clinical Trials

Auckland, , New Zealand

Site Status

Star Unit, North Shore Hospital, Waitemata District Health Board

Auckland, , New Zealand

Site Status

Southern Clinical Trials- Waitemata Ltd

Auckland, , New Zealand

Site Status

Clinical Horizons NZ Ltd

Tauranga, , New Zealand

Site Status

Hospital Conde de Bertiandos

Ponte de Lima, Viana do Castelo District, Portugal

Site Status

Medical Technologies Ltd.

Saint Petersburg, , Russia

Site Status

Institute of Rheumatology

Belgrade, , Serbia

Site Status

Kompan, s.r.o.

Dolný Kubín, , Slovakia

Site Status

Slovak Research Center Team Member, MUDr. Viliam Cibik, PhD, s.r.o.

Pruské, , Slovakia

Site Status

Instituto de Ciencias Medicas

Alicante, , Spain

Site Status

Hospital del Mar

Barcelona, , Spain

Site Status

Ladulaas Kliniska Studier

Boras, Sweden, , Sweden

Site Status

ProbarE I Lund AB

Lund, , Sweden

Site Status

ProbarE i Stockholm AB

Stockholm, , Sweden

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Canada Germany Hungary Italy Japan Lithuania New Zealand Portugal Russia Serbia Slovakia Spain Sweden

References

Explore related publications, articles, or registry entries linked to this study.

Mont MA, Carrino JA, Nemeth MA, Burr A, Yamabe T, Viktrup L, Brown MT, West CR, Verburg KM. Postoperative Outcome of Patients Who Underwent Total Joint Replacement During the Tanezumab Phase 3 Osteoarthritis Development Program: A 24-Week Observational Study. Surg Technol Int. 2021 May 20;38:467-477. doi: 10.52198/21.STI.38.OS1439.

Reference Type DERIVED
PMID: 34043229 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

Access external resources that provide additional context or updates about the study.

https://pmiform.com/clinical-trial-info-request?StudyID=A4091064

To obtain contact information for a study center near you, click here.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2013-002549-12

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

TJR FOLLOW-UP

Identifier Type: OTHER

Identifier Source: secondary_id

A4091064

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The MONOVISC Hip Osteoarthritis Study
NCT02698865 TERMINATED PHASE3
Rejuvenate Modular Outcomes Study
NCT01257568 COMPLETED NA
Survivorship of Attune Primary Total Knee Prosthesis
NCT01754363 ACTIVE_NOT_RECRUITING NA
Perform Humeral System Study
NCT05067543 RECRUITING
AEQUALIS™ FLEX REVIVE™ Study (REVIVE)
NCT05500066 ENROLLING_BY_INVITATION